Good Delivery Can Take You Everywhere

Aposense Molecular Nano-Motors (MNM) The First Gene Delivery Platform, Energized By The Internal Membrane Electrical Field.

About Us

Aposense is a highly innovative Israeli biotechnology company with full capacity research facilities and scientific leadership, headed by the Professor Roger D Kornberg, Nobel Prize Laureate, 2006. Aposense developed a universal platform entitled Molecular Nano-Motors (MNMs) for the delivery of genetic drugs, such as siRNA, into cells based on a novel mechanism of action, utilizing membrane electrical forces.

Aposense is focused on a novel and powerful natural energy resource : The Membrane Dipole Potential

Aposense pioneers in translational R&D of a recently-discovered voltage, that resides deep within any phospholipid membrane, and which is related to the membrane electric dipole potential. Due to the high hydrophobicity of biological membranes, the dipole potential translates into an enormously strong electric field of up to 1 billion V/m (!), spanning ~30 Å, from membrane surface to membrane center. Fascinated by the fact that every cell harbors its own discrete and strong powerhouse, Aposense developed rationally-designed molecular nano-motors (MNMs), being novel small-molecule chemical entities, capable of “energy mining” from the Internal Membrane Electric Field, and its translation into kinetic energy, for movement within the hydrophobic membrane core. Upon linkage to a genetic drug, this intra-membrane movement of the MNMs is utilized for enabling the delivery of genetic therapeutics namely siRNA into the cytoplasm, where they exert their pharmacological effects, e.g., gene silencing. Aposense Technology is the first utilization of this energy resource for medical applications.

These Molecular Nano-Motors (MNMs) are the core of our Technology

Aposense’s MNMs are pharmaceutically-compatible, small-molecule chemical moieties (MW≈800 Daltons), capable of moving within the core of cell membranes, energized by the internal electric field. We can efficiently control the Intra-membrane movement of the MNMs pharmacologically, and respectively, enable and control the related trans-membrane transport of a genetic cargo drug linked to the MNM, with delivery into practically any cell type. Furthermore, our delivery system comprises an innovative detachment moiety, selectively activated upon entry into cells, releasing and liberating the intact macro-molecule drug in the cytoplasm, to exert its biological action, while the MNM is excreted through the urine or bile.

Translating the vision of genetic therapeutics into a “druggable” reality